BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Lu J, Wu J, Mao L, Xu H, Wang S. Revisiting PD-1/PD-L pathway in T and B cell response: Beyond immunosuppression. Cytokine Growth Factor Rev 2022:S1359-6101(22)00052-1. [PMID: 35850949 DOI: 10.1016/j.cytogfr.2022.07.003] [Reference Citation Analysis]
2 Le TMD, Yoon AR, Thambi T, Yun CO. Polymeric Systems for Cancer Immunotherapy: A Review. Front Immunol 2022;13:826876. [PMID: 35273607 DOI: 10.3389/fimmu.2022.826876] [Reference Citation Analysis]
3 Lai F, Ji M, Huang L, Wang Y, Xue N, Du T, Dong K, Yao X, Jin J, Feng Z, Chen X. YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer. Acta Pharmaceutica Sinica B 2022;12:2845-58. [DOI: 10.1016/j.apsb.2022.02.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Amiri A, Bagherifar R, Ansari Dezfouli E, Kiaie SH, Jafari R, Ramezani R. Exosomes as bio-inspired nanocarriers for RNA delivery: preparation and applications. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03325-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Zhang J, Sun X, Zhao X, Yang C, Shi M, Zhang B, Hu H, Qiao M, Chen D, Zhao X. Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.05.008] [Reference Citation Analysis]
6 Zhang J, Sun X, Liu L, Zhao X, Yang C, Li K, Hu H, Qiao M, Chen D, Zhao X. Tumor-permeated ATP-based size-controllable immunogenic cell death amplifier remodel immunosuppressive microenvironment to boost cancer immunotherapy. Applied Materials Today 2022;28:101518. [DOI: 10.1016/j.apmt.2022.101518] [Reference Citation Analysis]